ClinicalTrials.gg
WithdrawnNCT00782301Updated Jan 19, 2012

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

A Phase 4 interventional study of maraviroc and etravirine in Hepatitis B, Human Immunodeficiency Virus and Hepatitis C, Chronic, sponsored by ViiV Healthcare. Withdrawn at 18 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-01-19.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Hepatitis B by GlaxoSmithKline — 2 open to participants now, 6 under way, none of them phase 3. Hepatitis B · GlaxoSmithKline.

Enrollment
136th of 137
0 · median 230
Started
2009
with 7 others
Phase 4
36 of 144
1 open now
Registered
81st of 144
by date

Among the 144 studies in Hepatitis B by GlaxoSmithKline, this one is the 136th largest by enrollment of the 137 interventional ones that give a count, is one of 8 that started in 2009, is one of 36 in phase 4, and was the 81st registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

2 of the 144 studies in Hepatitis B by GlaxoSmithKline are open now. Recruiting first, the newest first:

All 2 open studies →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Hepatitis B by GlaxoSmithKline, or all of them as a file.
02

Study summary

Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.

03

Conditions studied

  • Hepatitis B
  • Human Immunodeficiency Virus
  • Hepatitis C, Chronic

Keywords

  • HIV and Hepatitis co-infection
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-1 RNA viral load of ≥1000 copies/mL at the screening visit. Detectable levels or surface antigen (HBsAg) positive. Previous antiretroviral treatment experience with at least 2 antiretroviral drug classes for ≥3 months.

Documented resistance to an NNRTI as well as documented resistance to another antiretroviral agent.

CCR5 tropic virus detected by the TrofileTM assay.

Exclusion criteria

Exclusion Criteria:

Suspected or documented active, untreated -1 related Opportunistic Infection (OI) or other condition requiring acute therapy at the time of randomization (subjects on a stable (>1 month) secondary OI prophylaxis regimen are eligible for the study; subjects on a primary OI prophylaxis regimen of any duration are also eligible for the study).

Prior treatment with darunavir/ritonavir, raltegravir, or another integrase inhibitor, etravirine, maraviroc or another CCR5 inhibitor for more than 14 days at any time.

Subjects receiving treatment for chronic Hepatitis or the expected need to initiate treatment within 48 weeks of randomization. (Subjects who were previously treated for Hepatitis C are eligible for the study).

and/or ALT greater than 5 times the (ACTG Grade 3).

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Maraviroc

    Drug: maraviroc

  • Active comparator
    Etravirine

    Drug: etravirine

Interventions

  • maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.

    Also known as: Selzentry

  • etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT ≥100 IU/L through Week 48.

    Time frame: 48 weeks

Secondary outcomes

  1. Percentage of HCV treated subjects with Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT ≥100 IU/L through 96.

    Time frame: 48 weeks

  2. Time to development of Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT ≥100 IU/L.

    Time frame: 96 weeks

  3. Percentage of subjects with Hy's law abnormalities through Week 48.

    Time frame: 48 weeks

  4. Percentage of HCV treated subjects with Hy's law abnormalities through Week 96.

    Time frame: 96 weeks

  5. Change from baseline in mean Hepatitis C viral load through Week 48

    Time frame: 48 weeks

  6. Undetectable HCV viral load 24 weeks after stopping HCV treatment.

    Time frame: 240 weeks

  7. Percentage of subjects with HIV-1 RNA levels <48 copies/mL at Week 48.

    Time frame: 48 weeks

  8. Change from baseline in CD4+ cell count at Week 48.

    Time frame: 48 weeks

  9. Change from baseline in mean hepatitis B DNA through Week 48

    Time frame: 48 Weeks

07

Study locations

18 sites
  • Pfizer Investigational Site
    Clearwater, Florida 33765, United States
  • Pfizer Investigational Site
    Orlando, Florida 32803, United States
  • Pfizer Investigational Site
    Safety Harbor, Florida 34695, United States
  • Pfizer Investigational Site
    Wilton Manors, Florida 33305, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30308, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30312, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70112, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts 01605, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts 01655, United States
  • Pfizer Investigational Site
    Mt. Vernon, New York 10550, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74135, United States
  • Pfizer Investigational Site
    Bellaire, Texas 77401, United States
  • Pfizer Investigational Site
    Conroe, Texas 77301, United States
  • Pfizer Investigational Site
    Dallas, Texas 75390, United States
  • Pfizer Investigational Site
    Stafford, Texas 77477, United States
  • Pfizer Investigational Site
    Vancouver, British Columbia V6Z 2C7, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • Pfizer Investigational Site
    Bydgoszcz, 85-030, Poland
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2008
First posted
Oct 31, 2008
Start
Mar 2009
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Last update
Jan 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00782301
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Oct 31, 2008
Start date
Mar 2009
Primary completion
Feb 2010
Completion
Feb 2010
Last update
Jan 19, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Maraviroc · Etravirine

Start the discussion